To include your compound in the COVID-19 Resource Center, submit it here.

FDA issues notice about Kalydeco safety concern

FDA issued a notice about the potential for cataract development in children receiving cystic fibrosis drug

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE